Hims & Hers Health, Inc. (HIMS) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Hims & Hers Health, Inc. operates a consumer-first digital health platform providing access to prescription and non-prescription products, telehealth consultations, and wellness services. The company manages its operations as a single segment, focusing on sexual health, mental health, dermatology, and weight loss solutions.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Revenue | $586.0 million | $278.2 million | +111% |
| Gross Profit | $430.7 million | $229.1 million | +88% |
| Gross Margin | 73.5% | 82.4% | -8.9 pts |
| Operating Income | $57.9 million | $9.9 million | +485% |
| Net Income | $49.5 million | $11.1 million | +345% |
| Diluted EPS | $0.20 | $0.05 | +300% |
| Operating Cash Flow | $109.1 million | $25.8 million | +323% |
| Free Cash Flow | $50.1 million | $11.9 million | +321% |
| Cash & Equivalents | $273.7 million | $220.6 million | +24% |
| Debt | $0 (Undrawn) | $0 | N/A |
Note: The company entered into a $175 million revolving credit facility in February 2025, but no loans were outstanding as of March 31, 2025.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue more than doubled, driven primarily by a 115% increase in Online Revenue ($576.4 million). This growth was fueled by the launch of compounded GLP-1 weight loss offerings, which generated approximately $230 million in revenue during the quarter.
- Subscriber Growth: Total subscribers increased 38% to 2.37 million. Monthly Online Revenue per Average Subscriber rose 53% to $84, reflecting higher uptake of weight loss solutions.
- Margin Compression: Gross margin decreased from 82% to 73% due to the strategic pricing of new weight loss offerings and increased product costs associated with higher volume.
- Expense Increases: Marketing expenses rose 77% to $231.2 million, and Technology & Development expenses increased 95% to $29.9 million, reflecting heavy investment in customer acquisition and platform expansion.
- Acquisitions: The company acquired manufacturing assets from C S Bio Co. (approx. $39.1M consideration) and Trybe Labs ($5.1M) to strengthen supply chain and lab testing capabilities.
Guidance, Outlook, and Risks
- Regulatory Risk (GLP-1s): The FDA resolved the semaglutide shortage in February 2025. Management notes this constrains the ability to provide compounded semaglutide under enforcement discretion. While the company believes paths exist to continue offering compounded GLP-1s, future regulatory actions could impact this revenue stream.
- Investment Strategy: Management expects to continue significant investments in fulfillment, distribution, and marketing. They anticipate operating expenses will increase in the short term but expect long-term efficiency gains.
- Liquidity: The company maintains strong liquidity with $273.7 million in cash and a new $175 million credit facility. Management believes resources are sufficient for the next 12 months.
- Executive Changes: Nader Kabbani was appointed as Chief Operating Officer, effective May 19, 2025, to lead operational scaling.
Key Facts for Investor Verification
- Sustainability of GLP-1 Revenue: Verify the company's ability to maintain GLP-1 revenue streams post-FDA shortage resolution and potential regulatory shifts regarding compounding.
- Customer Acquisition Costs (CAC): Monitor the efficiency of the $201.6 million spent on customer acquisition to ensure long-term unit economics remain positive as marketing spend scales.
- Margin Trajectory: Assess whether gross margins stabilize as the company scales its new weight loss offerings and optimizes fulfillment costs.
- Capital Allocation: Track the utilization of the new $175 million credit facility and the $65 million remaining under the 2024 share repurchase program.
- Regulatory Compliance: Review ongoing FTC investigations and state-level regulatory actions regarding telehealth and marketing practices.